These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 4412113)

  • 1. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH; Stokes AL
    Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of L-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs.
    Minsker DH; Scriabine A; Stokes AL; Stone CA; Torchiana ML
    Experientia; 1971 May; 27(5):529-31. PubMed ID: 5132586
    [No Abstract]   [Full Text] [Related]  

  • 3. Localization of the site of the central sympatho-inhibitory action of 1-Dopa in dogs and cats.
    Schmitt H; Fenard S
    Eur J Pharmacol; 1973 May; 22(2):212-6. PubMed ID: 4715222
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 5. L-DOPA: centrally mediated emission of seminal fluid in male rats.
    Friedman E; Gershon S
    Life Sci I; 1972 May; 11(9):435-40. PubMed ID: 4656863
    [No Abstract]   [Full Text] [Related]  

  • 6. Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity of the rat locus ceruleus.
    Robert F; Lambás-Señas L; Ortemann C; Pujol JF; Renaud B
    J Neurochem; 1993 Feb; 60(2):721-9. PubMed ID: 8093483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
    Polleri A; Masturzo P; Murialdo G; Carolei A
    Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of noradrenaline synthesis in sympathetic nerves by carbidopa, an inhibitor of peripheral dopa decarboxylase.
    Wurtman RJ; Watkins CJ
    Nature; 1977 Jan; 265(5589):79-80. PubMed ID: 834247
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 11. The action L-dopa on sexual behaviour of male rats.
    Da Prada M; Carruba M; Saner A; O'Brien A; Pletscher A
    Brain Res; 1973 Jun; 55(2):383-9. PubMed ID: 4541349
    [No Abstract]   [Full Text] [Related]  

  • 12. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I; Van Woert MH
    Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbidopa attenuation of L-DOPA emesis in dogs: evidence for a cerebral site of action outside the blood-brain barrier.
    Lotti VJ; Clark C
    Eur J Pharmacol; 1974 Mar; 25(3):322-5. PubMed ID: 4827858
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of tyrosine-3-monooxygenase by benserazide.
    Reinhard JF; Shearin MD
    Biochem Pharmacol; 1990 May; 39(9):1489-91. PubMed ID: 1970732
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a decarboxylase inhibitor on the Dopa and 5-HTP induced changes in the locomotor-like discharge pattern of rabbit hind limb nerves.
    Viala D; Buser P
    Psychopharmacologia; 1974; 40(3):225-33. PubMed ID: 4548539
    [No Abstract]   [Full Text] [Related]  

  • 17. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of various agents on the pressor response to dopa in the anesthetized dog.
    Pruss TP; McGill JS
    Eur J Pharmacol; 1969 Oct; 8(1):14-8. PubMed ID: 4391043
    [No Abstract]   [Full Text] [Related]  

  • 20. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.